Cargando…

SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19

BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (Covid-19), which is most frequently mild yet can be severe and life-threatening. Virus-neutralizing monoclonal antibodies are predicted to reduce viral load, ameliorate symptoms, and prevent hos...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Peter, Nirula, Ajay, Heller, Barry, Gottlieb, Robert L., Boscia, Joseph, Morris, Jason, Huhn, Gregory, Cardona, Jose, Mocherla, Bharat, Stosor, Valentina, Shawa, Imad, Adams, Andrew C., Van Naarden, Jacob, Custer, Kenneth L., Shen, Lei, Durante, Michael, Oakley, Gerard, Schade, Andrew E., Sabo, Janelle, Patel, Dipak R., Klekotka, Paul, Skovronsky, Daniel M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Massachusetts Medical Society 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7646625/ https://www.ncbi.nlm.nih.gov/pubmed/33113295 http://dx.doi.org/10.1056/NEJMoa2029849

Ejemplares similares

Complete map of SARS-CoV-2 RBD mutations that escape the monoclonal antibody LY-CoV555 and its cocktail with LY-CoV016
por: Starr, Tyler N., et al.
Publicado: (2021)

Complete map of SARS-CoV-2 RBD mutations that escape the monoclonal antibody LY-CoV555 and its cocktail with LY-CoV016
por: Starr, Tyler N., et al.
Publicado: (2021)

The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates
por: Jones, Bryan E., et al.
Publicado: (2021)

Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19
por: Dougan, Michael, et al.
Publicado: (2021)

A Randomized, Placebo-Controlled Clinical Trial of Bamlanivimab and Etesevimab Together in High-Risk Ambulatory Patients With COVID-19 and Validation of the Prognostic Value of Persistently High Viral Load
por: Dougan, Michael, et al.
Publicado: (2021)

LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants
por: Westendorf, Kathryn, et al.
Publicado: (2022)

A Narrative Review of the Clinical Practicalities of Bamlanivimab and Etesevimab Antibody Therapies for SARS-CoV-2
por: Nathan, Ramesh, et al.
Publicado: (2021)

Clinical Impact of the Early Use of Monoclonal Antibody LY-CoV555 (Bamlanivimab) on Mortality and Hospitalization Among Elderly Nursing Home Patients: A Multicenter Retrospective Study
por: Alam, Mohammud M, et al.
Publicado: (2021)

Comparative highlights on MERS-CoV, SARS-CoV-1, SARS-CoV-2, and NEO-CoV
por: Goyal, Rajat, et al.
Publicado: (2022)

Human Coronaviruses SARS-CoV, MERS-CoV, and SARS-CoV-2 in Children
por: Aleebrahim-Dehkordi, Elahe, et al.
Publicado: (2021)

Data mining of coronavirus: SARS-CoV-2, SARS-CoV and MERS-CoV
por: Huh, Jung Eun, et al.
Publicado: (2021)

SARS-CoV, MERS-CoV and SARS-CoV-2: A Diagnostic Challenge
por: Ezhilan, Madeshwari, et al.
Publicado: (2021)

A Review of SARS-CoV2: Compared With SARS-CoV and MERS-CoV
por: Zhou, Huan, et al.
Publicado: (2021)

NeoCoV Is Closer to MERS-CoV than SARS-CoV
por: Hassan, Mohamed M, et al.
Publicado: (2020)

SARS-CoV, MERS-CoV and SARS-CoV-2 infections in pregnancy and fetal development
por: de Souza Silva, Guilherme Antonio, et al.
Publicado: (2020)

SARS-CoV-2, the other face to SARS-CoV and MERS-CoV: Future predictions
por: Abdelghany, T.M., et al.
Publicado: (2021)

Imaging findings in coronavirus infections: SARS-CoV, MERS-CoV, and SARS-CoV-2
por: Franquet, Tomas, et al.
Publicado: (2020)

Drug repurposing against SARS-CoV-1, SARS-CoV-2 and MERS-CoV
por: Aherfi, Sarah, et al.
Publicado: (2021)

Comparative susceptibility of SARS-CoV-2, SARS-CoV, and MERS-CoV across mammals
por: Li, Meng, et al.
Publicado: (2023)

LY6E Restricts Entry of Human Coronaviruses, Including Currently Pandemic SARS-CoV-2
por: Zhao, Xuesen, et al.
Publicado: (2020)

Computational analysis of SARS-CoV-2, SARS-CoV, and MERS-CoV genome using MEGA
por: Sohpal, Vipan Kumar
Publicado: (2020)

The Comparative Immunological Characteristics of SARS-CoV, MERS-CoV, and SARS-CoV-2 Coronavirus Infections
por: Zhang, Yun-yu, et al.
Publicado: (2020)

Comparison of the COVID-2019 (SARS-CoV-2) pathogenesis with SARS-CoV and MERS-CoV infections
por: Fani, Mona, et al.
Publicado: (2020)

The emerging SARS-CoV, MERS-CoV, and SARS-CoV-2: An insight into the viruses zoonotic aspects
por: Al-Salihi, Karima A., et al.
Publicado: (2021)

Transmission Cycle of SARS-CoV and SARS-CoV-2
por: Yadav, Tushar, et al.
Publicado: (2020)

A Comprehensive Review of Animal Models for Coronaviruses: SARS-CoV-2, SARS-CoV, and MERS-CoV
por: Singh, Ashutosh, et al.
Publicado: (2020)

Comparative Review of SARS-CoV-2, SARS-CoV, MERS-CoV, and Influenza A Respiratory Viruses
por: Abdelrahman, Zeinab, et al.
Publicado: (2020)

Autopsy Tool in Unknown Diseases: The Experience with Coronaviruses (SARS-CoV, MERS-CoV, SARS-CoV-2)
por: Sessa, Francesco, et al.
Publicado: (2021)

Immune Responses in SARS-CoV-2, SARS-CoV, and MERS-CoV Infections: A Comparative Review
por: Irani, Soussan
Publicado: (2022)

Comparative study: nonsynonymous and synonymous substitution of SARS-CoV-2, SARS-CoV, and MERS-CoV genome
por: Sohpal, Vipan Kumar
Publicado: (2021)

An Exploration of Nanoparticle-Based Diagnostic Approaches for Coronaviruses: SARS-CoV-2, SARS-CoV and MERS-CoV
por: Al-Hindawi, Ahmed, et al.
Publicado: (2022)

Potential recombination between SARS-CoV-2 and MERS-CoV: calls for the development of Pan-CoV vaccines
por: Wang, Qiao, et al.
Publicado: (2023)

Epidemiology of Deltacoronaviruses (δ-CoV) and Gammacoronaviruses (γ-CoV) in Wild Birds in the United States
por: Paim, Francine C., et al.
Publicado: (2019)

Monoclonal antibody treatment drives rapid culture conversion in SARS-CoV-2 infection
por: Boucau, Julie, et al.
Publicado: (2021)

Monoclonal antibody treatment drives rapid culture conversion in SARS-CoV-2 infection
por: Boucau, Julie, et al.
Publicado: (2022)

Comparison of the SARS-CoV-2 (2019-nCoV) M protein with its counterparts of SARS-CoV and MERS-CoV species
por: Alharbi, Sultan Nafea, et al.
Publicado: (2021)

MERS-CoV
por: Müller, Marcel A
Publicado: (2014)

What Binds Cationic Photosensitizers Better: Brownian Dynamics Reveals Key Interaction Sites on Spike Proteins of SARS-CoV, MERS-CoV, and SARS-CoV-2
por: Fedorov, Vladimir, et al.
Publicado: (2021)

Neurological Complications of SARS-CoV, MERS-CoV, and COVID-19
por: Alshebri, Munirah Saad, et al.
Publicado: (2020)

Comparing SARS-CoV-2 with SARS-CoV and influenza pandemics
por: Petersen, Eskild, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_8nma3echb22nrep81lhofvek97